Pulmonary function tests (PFTs) are integral to the diagnosis and management of respiratory diseases. However, their interpretation can be complex, requiring a comprehensive understanding of respiratory physiology and pathology. This guide aims to simplify the interpretation process for healthcare professionals.
Spirometry is the cornerstone of PFTs, providing information about airflow and lung volumes. Key parameters include Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and their ratio (FEV1/FVC). Abnormal results can indicate obstructive or restrictive lung diseases, with the pattern of changes providing diagnostic clues.
Diffusing capacity of the lungs for carbon monoxide (DLCO) assesses the efficiency of gas exchange across the alveolar-capillary membrane. Reduced DLCO may indicate conditions such as interstitial lung disease, pulmonary hypertension, or emphysema.
Total Lung Capacity (TLC), Functional Residual Capacity (FRC), and Residual Volume (RV) are measured using body plethysmography or gas dilution techniques. Elevated volumes suggest air trapping as seen in obstructive diseases, while reduced volumes indicate restrictive pathology.
Cardiopulmonary exercise testing (CPET) evaluates the integrative exercise responses involving the pulmonary, cardiovascular, hematopoietic, neuropsychological, and skeletal muscle systems. Abnormalities in oxygen uptake, ventilation, or heart rate responses can provide insights into the severity and nature of the disease.
Interpreting PFTs is a multifaceted process that requires a thorough understanding of the tests and their implications. Proficiency in PFT interpretation can greatly enhance clinical decision-making and patient management in respiratory medicine. As healthcare professionals, we must continually strive to enhance our skills in this critical area of practice.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation